- Home
- NRIM vs ABVX Comparison
NRIM vs ABVX Comparison
Compare NRIM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- ABVX
- Stock Information
- Founded
- NRIM 1990
- ABVX 2013
- Country
- NRIM United States
- ABVX France
- Employees
- NRIM N/A
- ABVX N/A
- Industry
- NRIM Savings Institutions
- ABVX
- Sector
- NRIM Finance
- ABVX
- Exchange
- NRIM Nasdaq
- ABVX Nasdaq
- Market Cap
- NRIM 500.9M
- ABVX 451.5M
- IPO Year
- NRIM N/A
- ABVX N/A
- Fundamental
- Price
- NRIM $91.19
- ABVX $7.74
- Analyst Decision
- NRIM
- ABVX Buy
- Analyst Count
- NRIM 0
- ABVX 4
- Target Price
- NRIM N/A
- ABVX $31.50
- AVG Volume (30 Days)
- NRIM 57.0K
- ABVX 221.8K
- Earning Date
- NRIM 07-23-2025
- ABVX 03-24-2025
- Dividend Yield
- NRIM 2.81%
- ABVX N/A
- EPS Growth
- NRIM 46.48
- ABVX N/A
- EPS
- NRIM 7.52
- ABVX N/A
- Revenue
- NRIM $164,695,000.00
- ABVX $11,456,982.00
- Revenue This Year
- NRIM N/A
- ABVX $284.20
- Revenue Next Year
- NRIM $7.25
- ABVX N/A
- P/E Ratio
- NRIM $12.13
- ABVX N/A
- Revenue Growth
- NRIM 26.35
- ABVX 135.94
- 52 Week Low
- NRIM $52.10
- ABVX $4.77
- 52 Week High
- NRIM $92.45
- ABVX $14.71
- Technical
- Relative Strength Index (RSI)
- NRIM 68.06
- ABVX 71.01
- Support Level
- NRIM $86.00
- ABVX $5.59
- Resistance Level
- NRIM $92.45
- ABVX $6.09
- Average True Range (ATR)
- NRIM 2.23
- ABVX 0.40
- MACD
- NRIM -0.15
- ABVX 0.13
- Stochastic Oscillator
- NRIM 80.47
- ABVX 93.92
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.